-
Je něco špatně v tomto záznamu ?
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells
MAM. Rodrigo, H. Michalkova, AMJ. Jimenez, F. Petrlak, T. Do, L. Sivak, Y. Haddad, P. Kubickova, V. de Los Rios, JI. Casal, M. Serrano-Macia, TC. Delgado, L. Boix, J. Bruix, ML. Martinez Chantar, V. Adam, Z. Heger
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
759585
European Research Council - International
759585
European Research Council - International
759585
European Research Council - International
759585
European Research Council - International
759585
European Research Council - International
759585
European Research Council - International
NLK
BioMedCentral
od 2013-12-01
BioMedCentral Open Access
od 2013
Directory of Open Access Journals
od 2013
Free Medical Journals
od 2013
PubMed Central
od 2013
Europe PubMed Central
od 2013
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2013-01-01
Open Access Digital Library
od 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
Springer Nature OA/Free Journals
od 2013-12-01
- Publikační typ
- časopisecké články MeSH
BACKGROUND & AIMS: Metallothionein-3 (hMT3) is a structurally unique member of the metallothioneins family of low-mass cysteine-rich proteins. hMT3 has poorly characterized functions, and its importance for hepatocellular carcinoma (HCC) cells has not yet been elucidated. Therefore, we investigated the molecular mechanisms driven by hMT3 with a special emphasis on susceptibility to sorafenib. METHODS: Intrinsically sorafenib-resistant (BCLC-3) and sensitive (Huh7) cells with or without up-regulated hMT3 were examined using cDNA microarray and methods aimed at mitochondrial flux, oxidative status, cell death, and cell cycle. In addition, in ovo/ex ovo chick chorioallantoic membrane (CAM) assays were conducted to determine a role of hMT3 in resistance to sorafenib and associated cancer hallmarks, such as angiogenesis and metastastic spread. Molecular aspects of hMT3-mediated induction of sorafenib-resistant phenotype were delineated using mass-spectrometry-based proteomics. RESULTS: The phenotype of sensitive HCC cells can be remodeled into sorafenib-resistant one via up-regulation of hMT3. hMT3 has a profound effect on mitochondrial respiration, glycolysis, and redox homeostasis. Proteomic analyses revealed a number of hMT3-affected biological pathways, including exocytosis, glycolysis, apoptosis, angiogenesis, and cellular stress, which drive resistance to sorafenib. CONCLUSIONS: hMT3 acts as a multifunctional driver capable of inducing sorafenib-resistant phenotype of HCC cells. Our data suggest that hMT3 and related pathways could serve as possible druggable targets to improve therapeutic outcomes in patients with sorafenib-resistant HCC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013041
- 003
- CZ-PrNML
- 005
- 20240726151508.0
- 007
- ta
- 008
- 240723s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s40364-024-00584-y $2 doi
- 035 __
- $a (PubMed)38594765
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rodrigo, Miguel Angel Merlos $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic. miguel.rodrigo@mendelu.cz
- 245 10
- $a Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells / $c MAM. Rodrigo, H. Michalkova, AMJ. Jimenez, F. Petrlak, T. Do, L. Sivak, Y. Haddad, P. Kubickova, V. de Los Rios, JI. Casal, M. Serrano-Macia, TC. Delgado, L. Boix, J. Bruix, ML. Martinez Chantar, V. Adam, Z. Heger
- 520 9_
- $a BACKGROUND & AIMS: Metallothionein-3 (hMT3) is a structurally unique member of the metallothioneins family of low-mass cysteine-rich proteins. hMT3 has poorly characterized functions, and its importance for hepatocellular carcinoma (HCC) cells has not yet been elucidated. Therefore, we investigated the molecular mechanisms driven by hMT3 with a special emphasis on susceptibility to sorafenib. METHODS: Intrinsically sorafenib-resistant (BCLC-3) and sensitive (Huh7) cells with or without up-regulated hMT3 were examined using cDNA microarray and methods aimed at mitochondrial flux, oxidative status, cell death, and cell cycle. In addition, in ovo/ex ovo chick chorioallantoic membrane (CAM) assays were conducted to determine a role of hMT3 in resistance to sorafenib and associated cancer hallmarks, such as angiogenesis and metastastic spread. Molecular aspects of hMT3-mediated induction of sorafenib-resistant phenotype were delineated using mass-spectrometry-based proteomics. RESULTS: The phenotype of sensitive HCC cells can be remodeled into sorafenib-resistant one via up-regulation of hMT3. hMT3 has a profound effect on mitochondrial respiration, glycolysis, and redox homeostasis. Proteomic analyses revealed a number of hMT3-affected biological pathways, including exocytosis, glycolysis, apoptosis, angiogenesis, and cellular stress, which drive resistance to sorafenib. CONCLUSIONS: hMT3 acts as a multifunctional driver capable of inducing sorafenib-resistant phenotype of HCC cells. Our data suggest that hMT3 and related pathways could serve as possible druggable targets to improve therapeutic outcomes in patients with sorafenib-resistant HCC.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Michalkova, Hana $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic
- 700 1_
- $a Jimenez, Ana Maria Jimenez $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic
- 700 1_
- $a Petrlak, Frantisek $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic
- 700 1_
- $a Do, Tomas $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic
- 700 1_
- $a Sivak, Ladislav $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic
- 700 1_
- $a Haddad, Yazan $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic
- 700 1_
- $a Kubickova, Petra $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic
- 700 1_
- $a de Los Rios, Vivian $u Department of Cellular and Molecular Medicine and Proteomic Facility, Centro de Investigaciones Biológicas (CIB-CSIC), Ramiro de Maeztu 9, Madrid, 280 40, Spain
- 700 1_
- $a Casal, J Ignacio $u Department of Cellular and Molecular Medicine and Proteomic Facility, Centro de Investigaciones Biológicas (CIB-CSIC), Ramiro de Maeztu 9, Madrid, 280 40, Spain
- 700 1_
- $a Serrano-Macia, Marina $u Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, 48160, Spain
- 700 1_
- $a Delgado, Teresa C $u Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, 48160, Spain
- 700 1_
- $a Boix, Loreto $u Barcelona-Clínic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Bruix, Jordi $u Barcelona-Clínic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Martinez Chantar, Maria L $u Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, 48160, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Adam, Vojtech $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic
- 700 1_
- $a Heger, Zbynek $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ-613 00, Czech Republic. zbynek.heger@mendelu.cz
- 773 0_
- $w MED00205975 $t Biomarker research $x 2050-7771 $g Roč. 12, č. 1 (2024), s. 38
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38594765 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151500 $b ABA008
- 999 __
- $a ok $b bmc $g 2125572 $s 1224904
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 12 $c 1 $d 38 $e 20240409 $i 2050-7771 $m Biomarker research $n Biomark Res $x MED00205975
- GRA __
- $a 759585 $p European Research Council $2 International
- GRA __
- $a 759585 $p European Research Council $2 International
- GRA __
- $a 759585 $p European Research Council $2 International
- GRA __
- $a 759585 $p European Research Council $2 International
- GRA __
- $a 759585 $p European Research Council $2 International
- GRA __
- $a 759585 $p European Research Council $2 International
- LZP __
- $a Pubmed-20240723